CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Accretion Nutraveda Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Accretion Nutraveda Ltd
27 Xcelon Industrial Park-1
Vasna-Chacharwadi
AHMEDABAD, 382213  India Ticker: 544694544694
Business Summary
Accretion Nutraveda Limited is an India-based healthcare focused company. The Company is engaged in the manufacturing and sale of pharmaceutical products. It is engaged in the manufacturing of Ayurvedic and Nutraceutical products across multiple dosage forms, which include tablets, capsules, oral liquids, oral powders, external preparations, and oils. Its product portfolio includes tablets such as film-coated and chewable forms, intended for applications related to liver care, gynecological care, bone and joint health, and respiratory support. It also manufactures capsules directed towards liver detoxification, women’s health, and cognitive support. Its oral liquid products include syrups, suspensions, tonics, and traditional decoctions, formulated for paediatric and geriatric applications. It also produces traditional Ayurvedic powders, known as churans, for digestive health, medicated Ayurvedic oils used in musculoskeletal and dermatological treatments.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20253/31/2025-----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations

General Information
Stock Exchange: BOM


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, February 4, 2026